LLY Quote, Financials, Valuation and Earnings

Moderna has a net margin of 32.59% compared to Eli Lilly and's net margin of -117.16%. Eli Lilly and's return on equity of 80.24% beat Moderna's return on equity of -29.09%.

Eli Lilly and has a consensus price target of $1,010.47, signalling upside risk potential of 22.85%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 74.24%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.342, which suggesting that the stock is 65.817% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.66%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $13.5B, which are larger than Moderna quarterly revenues of $956M. Eli Lilly and's net income of $4.4B is higher than Moderna's net income of -$1.1B. Notably, Eli Lilly and's price-to-earnings ratio is 70.24x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 16.51x versus 3.77x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 32.59% compared to Eli Lilly and's net margin of 24.22%. Eli Lilly and's return on equity of 80.24% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Eli Lilly and has a consensus price target of $1,010.47, signalling upside risk potential of 22.85%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 44.82%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.342, which suggesting that the stock is 65.817% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.66%. Regeneron Pharmaceuticals offers a yield of 0.14% to investors and pays a quarterly dividend of $0.88 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $13.5B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Eli Lilly and's net income of $4.4B is higher than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Eli Lilly and's price-to-earnings ratio is 70.24x while Regeneron Pharmaceuticals's PE ratio is 16.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 16.51x versus 5.16x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 32.59% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 80.24% beat Viking Therapeutics's return on equity of --.

Eli Lilly and has a consensus price target of $1,010.47, signalling upside risk potential of 22.85%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 276.97%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.342, which suggesting that the stock is 65.817% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.66%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $13.5B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $4.4B is higher than Viking Therapeutics's net income of -$35.4M. Notably, Eli Lilly and's price-to-earnings ratio is 70.24x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 16.51x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 32.59% compared to Eli Lilly and's net margin of 31.35%. Eli Lilly and's return on equity of 80.24% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Eli Lilly and has a consensus price target of $1,010.47, signalling upside risk potential of 22.85%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.19 which suggests that it could fall by -0.62%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

Eli Lilly and has a beta of 0.342, which suggesting that the stock is 65.817% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.66%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $13.5B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.9B. Eli Lilly and's net income of $4.4B is higher than Vertex Pharmaceuticals's net income of $913M. Notably, Eli Lilly and's price-to-earnings ratio is 70.24x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 16.51x versus 11.77x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.